A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.Kevin Kalinsky, Dawn L. Hershman, Meghna S. Trivedi et al.|Journal of Clinical Oncology|2022Cited by 73
Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).Qamar J. Khan, Priyanka Sharma, Anne O’Dea et al.|Journal of Clinical Oncology|2020Cited by 68